Quoin Pharmaceuticals Reports $1.77/Share Q1 Loss, Extending Financial Challenges
QNRX sits 22% above its 52-week low of $5.2 on light trading volume (0.1× avg).
Summary
Quoin Pharmaceuticals reported a first-quarter loss of $1.77 per share, signaling a continuation of the significant financial challenges highlighted in its recent 10-K filing. This specific Q1 result provides new, concrete evidence of ongoing cash burn and operational losses for the micro-cap biotech firm. For a company with a market capitalization under $10 million, a loss of this magnitude relative to its share price ($6.34) is highly material and reinforces concerns about its long-term viability and potential need for further dilutive financing. Traders will closely monitor future regulatory updates and any capital raising efforts.
At the time of this announcement, QNRX was trading at $6.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.6M. The 52-week trading range was $5.20 to $41.80. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.